Table 2.
Correlation of tumor CCT6A expression with clinical features
| Items | Tumor CCT6A expression | P value | |
|---|---|---|---|
| Low (n = 200) | High (n = 181) | ||
| Age, No. (%) | 0.239 | ||
| ≤60.0 years | 106 (53.0) | 85 (47.0) | |
| >60.0 years | 94 (47.0) | 96 (53.0) | |
| Gender, No. (%) | 0.458 | ||
| Female | 53 (26.5) | 42 (23.2) | |
| Male | 147 (73.5) | 139 (76.8) | |
| History of smoke, No. (%) | 0.107 | ||
| No | 83 (41.5) | 90 (49.7) | |
| Yes | 117 (58.5) | 91 (50.3) | |
| History of drink, No. (%) | 0.565 | ||
| No | 124 (62.0) | 107 (59.1) | |
| Yes | 76 (38.0) | 74 (40.9) | |
| Hypertension, No. (%) | 0.774 | ||
| No | 122 (61.0) | 113 (62.4) | |
| Yes | 78 (39.0) | 68 (37.6) | |
| Hyperlipidemia, No. (%) | 0.824 | ||
| No | 136 (68.0) | 125 (69.1) | |
| Yes | 64 (32.0) | 56 (30.9) | |
| Diabetes, No. (%) | 0.479 | ||
| No | 170 (85.0) | 149 (82.3) | |
| Yes | 30 (15.0) | 32 (17.7) | |
| Differentiation, No. (%) | 0.627 | ||
| Well | 35 (17.5) | 21 (11.6) | |
| Moderate | 112 (56.0) | 116 (64.1) | |
| Poor | 53 (26.5) | 44 (24.3) | |
| Tumor size, No. (%) | 0.106 | ||
| ≤5.0 cm | 130 (65.0) | 103 (56.9) | |
| >5.0 cm | 70 (35.0) | 78 (43.1) | |
| LYN metastasis, No. (%) | 0.001 | ||
| No | 145 (72.5) | 102 (56.4) | |
| Yes | 55 (27.5) | 79 (43.6) | |
| TNM stage, No. (%) | 0.002 | ||
| I | 82 (41.0) | 49 (27.1) | |
| II | 55 (27.5) | 52 (28.7) | |
| III | 63 (31.5) | 80 (44.2) | |
| CEA, No. (%) | 0.022 | ||
| Normal (≤5.0 ng/mL) | 95 (47.5) | 65 (35.9) | |
| Abnormal (>5.0 ng/mL) | 105 (52.5) | 116 (64.1) | |
Comparison was determined by chi-square test or Wilcoxon rank-sum test. CCT6A chaperonin containing TCP1 subunit 6A; LYN lymph node; CEA carcinoembryonic antigen